How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?
Vibor MilunovićPublished in: Medicina (Kaunas, Lithuania) (2024)
Hodgkin lymphoma is characterized by a high cure rate in the modern era of medicine regardless of stage, but patients suffer from a high risk of comorbidity associated with the administered therapy. The main aim of this review article is to assess and analyze the various comorbidities associated with Hodgkin lymphoma and address the survivorship of patients, including fertility, secondary cancers due to cardiovascular toxicity, and quality of life. Furthermore, this review explores the optimal strategy for detecting relapse. The treatment paradigm of Hodgkin lymphoma has shifted, with a paradigm shift toward achieving a high cure rate and low toxicity as a standard of care in this patient population. Checkpoint inhibitors, especially nivolumab, in combination with chemotherapy are increasingly being studied in the first line of therapy. However, their long-term toxicity remains to be assessed in longer follow-up. In conclusion, Hodgkin lymphoma survivors, regardless of their treatment, should be followed up individually by a multidisciplinary survivorship team in order to detect and properly treat the long-term side effects of therapy.
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- oxidative stress
- healthcare
- peritoneal dialysis
- dna damage
- quality improvement
- squamous cell carcinoma
- childhood cancer
- mesenchymal stem cells
- cell proliferation
- rheumatoid arthritis
- combination therapy
- patient reported outcomes
- disease activity
- systemic lupus erythematosus
- locally advanced
- cell therapy
- rectal cancer
- smoking cessation
- free survival
- oxide nanoparticles